Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 4 3Phase 1 3Phase 1/2 2

Status

Completed 2Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 4NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 3Other hematologic neoplasm 1

Conditions

Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Pancreatic Neoplasms 1Liver Neoplasms 1Hematologic Neoplasms 1Hematologic Diseases 1Clostridium Infections 1

Interventions

pembrolizumab 514Specimen Handling 382Carboplatin 372Magnetic Resonance Spectroscopy 333Cisplatin 327Nivolumab 303Cyclophosphamide 295Radiotherapy 255Paclitaxel 252Biopsy 235Gemcitabine 231Bevacizumab 212Dexamethasone 167durvalumab 162Oxaliplatin 160Capecitabine 155Rituximab 152Fluorouracil 148venetoclax 143Docetaxel 143atezolizumab 141Drug Therapy 140Etoposide 139Doxorubicin 131Ipilimumab 126Radiosurgery 118Prednisone 117Lenalidomide 117Leucovorin 111fludarabine 109

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Vancomycin × 1 year × Clear all
NCT03030248 2026-04-15

Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients

Medical College of Wisconsin

Phase 2 Completed
9 enrolled 9 charts

Clostridium Infections, Hematologic Diseases

NCT04983901 2026-04-06

PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN

M.D. Anderson Cancer Center

Phase 2 Completed
100 enrolled 38 charts
Other hematologic neoplasm

Hematologic Neoplasms

NCT03785210 2026-02-23

Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
22 enrolled 13 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04729322 2025-12-23

Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
15 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT05690048 2025-08-06

FLORA

University Hospital Heidelberg

Phase 2 Recruiting
48 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡